Caris Life Sciences to Showcase Innovative Research at AACR
Caris Life Sciences, a pivotal player in next-generation AI technology and precision medicine, is making a significant impact in cancer research. The company announced its participation in the upcoming American Association for Cancer Research (AACR) Annual Meeting, where it will present 14 abstracts across nine tumor types, illustrating the power of collaboration in precision oncology.
The Highlights of the Presentation
At this year's conference, running from April 25 to April 30, Caris and its collaborators within the Caris Precision Oncology Alliance will share valuable research findings. The abstracts cover a broad spectrum of cancer types, including gastro-esophageal, lung, and pancreatic cancers, utilizing Caris' extensive clinic-genomic datasets. The variety of studies highlights the importance of comprehensive molecular profiling in advancing cancer treatment.
Executive Insights
"We are thrilled about the abstracts accepted for presentation at AACR this year, emphasizing the importance of our collaborative work within the Caris POA," said George W. Sledge, Jr., MD, Chief Medical Officer of Caris. This statement underscores the commitment of Caris Life Sciences to leverage cutting-edge research methodologies to better understand cancer pathology and improve clinical outcomes.
James Hamrick, MD, MPH, Chairman of the Caris Precision Oncology Alliance, echoed similar sentiments, expressing how the collaborative efforts empower clinicians and facilitate essential advancements in cancer care.
Key Presentations and Innovations
Among the sessions scheduled, notable minisymposium presentations will include groundbreaking research on various oncological topics:
- Pre-operative abemaciclib in localized cisplatin-ineligible MIBC with tissue and ctDNA molecular response validation (Abstract Number CT127)
- Kinase fusion landscape of pancreatic cancer (Abstract Number 3781)
Poster Presentations
In addition to oral presentations, several critical poster presentations will occur, including:
- Clinical, biologic, and immunogenic characteristics of gastro-esophageal cancers harboring CLDN18::ARHGAP fusions (Poster Number 496/8)
- Functional characterization of SMARCA4 genomic variants (Poster Number 674/7)
- Targeting ATM to enhance chemotherapy efficacy in small cell lung cancer (Poster Number LB016/16)
- Association of cyclin E1 expression with genomic instability in ovarian cancer (Poster Number 2846/13)
Booth Presentation and Resources
Attendees looking for detailed insights can visit Caris' booth #400, where summaries of the research, along with the full abstracts, will be available after the presentations. This initiative emphasizes transparency and the dissemination of vital cancer research findings.
The Caris Precision Oncology Alliance
The Caris POA comprises 96 esteemed cancer centers, research consortiums, and healthcare systems, including 47 NCI-designated cancer centers. This collaborative network is committed to enhancing precision oncology standards and promoting robust biomarker-driven research, ultimately aiming to improve treatment outcomes for cancer patients.
About Caris Life Sciences
Founded with a mission to revolutionize healthcare through precision medicine, Caris Life Sciences utilizes advanced molecular profiling techniques such as Whole Exome and Whole Transcriptome Sequencing. Their innovative approach combines big data with AI and machine learning algorithms to create a comprehensive database aimed at unraveling the complexities of diseases.
Headquartered in Texas, Caris Life Sciences maintains a global presence, working diligently to deliver advanced solutions for improved cancer treatment. Their commitment to improving the human condition through pioneering healthcare technologies continues to set them apart in the field of precision medicine.
Frequently Asked Questions
What is Caris Life Sciences known for?
Caris Life Sciences is recognized as a leading company in precision medicine, specializing in comprehensive molecular profiling and innovative AI technology.
What will Caris present at the AACR Annual Meeting?
Caris will present 14 abstracts covering various tumor types, showcasing research that highlights the significance of their precision oncology collaborations.
How does the Caris Precision Oncology Alliance contribute to cancer research?
The Caris POA facilitates collaboration among cancer centers and healthcare systems to advance molecular testing and improve outcomes for patients.
When is the AACR Annual Meeting?
The AACR Annual Meeting will take place from April 25-30.
Where can one find more information about the presented research?
Research summaries and full abstracts will be available at Caris' booth during the event and on their website following the conference.
